Polycythemia Vera

Detailed Overview

The disease is almost universally driven by a somatic mutation in the JAK2 gene (JAK2 V617F). This mutation causes the hematopoietic stem cells to become hypersensitive to or independent of growth factors like erythropoietin. The massively increased red blood cell mass drastically increases blood viscosity, leading to sluggish blood flow, tissue hypoxia, and a profound risk of arterial and venous thromboses (stroke, myocardial infarction, DVT, Budd-Chiari syndrome). Over time, the hyperactive bone marrow can 'burn out,' transforming into myelofibrosis, or rarely, acute myeloid leukemia (AML).

Epidemiology & Demographics

Incidence is 1-2 per 100,000 annually. Prevalence is approximately 22 per 100,000. Median age at diagnosis is 60 years. Slightly more common in men.

Etiological Mechanism

An acquired genetic disorder. Over 95% of patients carry the JAK2 V617F mutation in exon 14. An additional 3-4% have mutations in JAK2 exon 12. Familial cases are extremely rare.

Primary Causes

Clonal stem cell mutation activating the JAK-STAT signaling pathway, driving unchecked myelopoiesis.

• Age: Risk strongly correlates with advancing age; uncommon under age 40.
• Radiation/Toxin Exposure: Previous exposure to high-dose ionizing radiation or chronic benzene exposure (weak link).

The JAK2 tyrosine kinase is normally coupled to the erythropoietin (EPO) receptor. When EPO binds, JAK2 phosphorylates STAT proteins to signal RBC production. The JAK2 V617F mutation causes the kinase to be constitutively active, constantly signaling the marrow to produce erythrocytes, leukocytes, and megakaryocytes even in the complete absence of EPO. The resulting polycythemia hyperviscosity leads to high shear stress on endothelial cells, activating platelets and promoting thrombosis. Increased cell turnover leads to hyperuricemia, and increased histamine release from basophils causes profound itching.

Characteristic Clinical Presentation

• Aquagenic Pruritus: Severe, burning itching triggered by contact with water (especially warm showers), highly characteristic of PV.
• Hyperviscosity Symptoms: Headache, dizziness, tinnitus, blurred vision, and debilitating fatigue.
• Erythromelalgia: Intense burning pain and redness in the hands and feet caused by microvascular occlusions.
• Bleeding/Bruising: Paradoxical mucosal bleeding (epistaxis, GI bleeds) due to acquired von Willebrand syndrome in extreme thrombocytosis.

Physical Examination Signs

• Plethora (ruddy, red complexion, especially of the face, palms, and conjunctivae)
• Splenomegaly (present in 75% of patients due to extramedullary hematopoiesis or splenic vein thrombosis)
• Hepatomegaly
• Gouty tophi or swollen joints (due to hyperuricemia)

• Thrombosis: The leading cause of death. Includes stroke, MI, DVT, PE, and unusual site thromboses like hepatic vein (Budd-Chiari syndrome) or portal vein thrombosis.
• Myelofibrosis: Occurs in 10-15% of patients after 10-15 years.
• Acute Myeloid Leukemia (AML): Transforms in 2-5% of patients, carrying a very poor prognosis.

Diagnostic Criteria & Guidelines

WHO 2016 Criteria require all 3 major, or first 2 major + 1 minor. Major: 1) Hemoglobin >16.5 g/dL (men) or >16.0 g/dL (women), OR Hematocrit >49% (men) or >48% (women). 2) Bone marrow biopsy showing hypercellularity with panmyelosis. 3) Presence of JAK2 V617F or JAK2 exon 12 mutation. Minor: Subnormal serum erythropoietin (EPO) level.

Differential Diagnosis

• Secondary Polycythemia (due to hypoxia from COPD, sleep apnea, or smoking - EPO will be HIGH)
• EPO-secreting tumors (Renal cell carcinoma, hepatocellular carcinoma - EPO will be HIGH)
• Relative Polycythemia (Gaisböck syndrome, hemoconcentration due to severe dehydration)
• Essential Thrombocythemia (if platelets are the primary elevated line)

Laboratory Tests & Biomarkers

• Hemoglobin / Hematocrit: Markedly elevated (e.g., Hct 55-60%).
• Serum Erythropoietin (EPO): Very low or undetectable (<4 mU/mL), distinguishing it from secondary polycythemia.
• JAK2 Mutation Analysis: Positive for V617F (peripheral blood PCR).
• WBC and Platelets: Elevated (WBC >12,000/μL, Platelets >450,000/μL).

Imaging Modalities & Findings

• Abdominal Ultrasound:

• Prodromal/Pre-polycythemic Phase
  Borderline erythrocytosis, often discovered incidentally on routine CBC.
• Overt Polycythemic Phase
  Significant increase in red cell mass, panmyelosis, severe hyperviscosity symptoms, and high thrombosis risk.
• Spent Phase (Post-PV Myelofibrosis)
  Marrow burns out and becomes fibrotic. Cytopenias replace cytoses. Massive splenomegaly as spleen takes over blood production.

Second-Line & Adjunctive Therapy

For younger patients requiring cytoreduction or those intolerant to hydroxyurea: Pegylated Interferon alfa-2a (Pegasys). For patients refractory to hydroxyurea with severe pruritus or splenomegaly: Ruxolitinib (JAK1/2 inhibitor, 10-20 mg PO BID).

Surgical & Procedural Management

Rarely, splenectomy for massive, painful, refractory splenomegaly in the spent phase.

Recommended Lifestyle Changes

Patient Counseling & Advice

Educate the patient that PV is a chronic, lifelong blood cancer, but it is manageable. Explain that the goal of taking their blood (phlebotomy) is to make them iron deficient, which slows down the bone marrow. Emphasize the critical importance of taking daily aspirin and keeping appointments to check hematocrit to prevent fatal blood clots.

Follow-Up & Monitoring Schedule

Check CBC every 2-4 weeks until Hematocrit is stabilized <45%. Once stable, monitor CBC every 3 months. Monitor for symptoms of disease progression (increasing spleen size, massive weight loss, severe night sweats).

Preventive Strategies

No prevention available. Focus is on preventing thrombotic complications.

With strict control of hematocrit, median survival approaches 20 years, slightly less than the age-matched general population. The primary risk to life is a thrombotic event or transformation to AML.